HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy

Journal of Rheumatology

Volumn 40, Issue 1, 2013, Pages 96-97

  Lee, Ming Han Hugo ^a   Stocker, Sophie Lena ^a   Williams, Kenneth Mapson ^a   Day, Richard Osborne ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AMLODIPINE; ATENOLOL; ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; CYCLOSPORIN; FELODIPINE; GLUCOCORTICOID; HLA B ANTIGEN; HLA B5801 ANTIGEN; IRBESARTAN; METOPROLOL; NIFEDIPINE; PREDNISONE; UNCLASSIFIED DRUG; HLA B*58:01 ANTIGEN; HLA-B*58:01 ANTIGEN;

AGED; ALLELE; BLISTER; CASE REPORT; CHINESE; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DNA SEQUENCE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EOSINOPHILIA; ESSENTIAL HYPERTENSION; FAMILY HISTORY; FEVER; GENOTYPE; GOUT; HETEROZYGOTE; HLA SYSTEM; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SKIN BIOPSY; STEROID THERAPY; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; ASIAN; CHEMICALLY INDUCED DISORDER; GENETIC SCREENING; GENETICS; RISK;

ALLOPURINOL; ARTHRITIS, GOUTY; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC TESTING; HLA-B ANTIGENS; HUMANS; RISK; STEVENS-JOHNSON SYNDROME;

EID: 84871880477     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120803     Document Type: Letter

References (10)

1. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981;40:245-9. (Pubitemid 11122536)
2. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44. (Pubitemid 350249390)
3. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9. (Pubitemid 40388568)
4. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Hasegawa R, Aihara M, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2011 Sep 13 [E-pub ahead of print].
5. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
6. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-9.
7. Chiu ML, Hu M, Ng MH, Yeung CK, Chan JC, Chang MM, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012;167:44-9.
8. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.
9. Lee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, et al. Initiating allopurinol therapy: Do we need to know the patient's human leucocyte antigen status? Intern Med J 2012;42:411-6.
10. Love BL, Barrons R, Veverka A, Snider KM. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 2010;30:594-608.